Company research
CVRx, Inc.
CIK 1235912Updated Sep 24, 2026
SecurityCVRX · NASDAQ · equity
Name history
CVRX INC · through Jul 15, 2013
CVRX price & chart
Loading TradingView…
NASDAQ:CVRX on TradingView ↗About the company
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 104,794,000Source | 133,414,000Source | 115,229,000Source | 124,937,000Source |
| Property, Plant and Equipment, NetUSD | 2,243,000Source | 2,505,000Source | 1,763,000Source | 1,698,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 75,708,000Source | 105,933,000Source | 90,569,000Source | 106,194,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 10,665,000Source | 9,268,000Source | 7,551,000Source | 5,504,000Source |
| Inventory, NetUSD | 12,205,000Source | 12,107,000Source | 10,983,000Source | 6,957,000Source |
| Assets, CurrentUSD | 101,647,000Source | 129,813,000Source | 112,090,000Source | 122,878,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,069,000Source | 2,505,000Source | 2,987,000Source | 4,223,000Source |
| Operating Lease, Right-of-Use AssetUSD | 878,000Source | 1,069,000Source | 1,349,000Source | 334,000Source |
| Other Assets, NoncurrentUSD | 26,000Source | 27,000Source | 27,000Source | 27,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 65,470,000Source | 62,359,000Source | 39,282,000Source | 15,757,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 263,000Source | 253,000Source | 209,000Source | 207,000Source |
| Retained Earnings (Accumulated Deficit)USD | -590,652,000Source | -537,346,000Source | -477,381,000Source | -436,182,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -203,000Source | -206,000Source | -207,000Source | -207,000Source |
| Stockholders' Equity Attributable to ParentUSD | 39,324,000Source | 71,055,000Source | 75,947,000Source | 109,180,000Source |
| Additional Paid in Capital, Common StockUSD | 629,916,000Source | 608,354,000Source | 553,326,000Source | 545,362,000Source |
| Liabilities and EquityUSD | 104,794,000Source | 133,414,000Source | 115,229,000Source | 124,937,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 13,317,000Source | 10,762,000Source | 7,864,000Source | 8,088,000Source |
| Operating Lease, Liability, CurrentUSD | 352,000Source | 282,000Source | 231,000Source | 222,000Source |
| Accounts Payable, CurrentUSD | 3,833,000Source | 2,582,000Source | 1,884,000Source | 1,719,000Source |
| Operating Lease, Liability, NoncurrentUSD | 638,000Source | 877,000Source | 1,160,000Source | 117,000Source |
| Other Liabilities, NoncurrentUSD | 2,001,000Source | 1,447,000Source | 1,036,000Source | 805,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 9,484,000Source | 8,180,000Source | 5,980,000Source | 6,369,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 49,514,000Source | 49,273,000Source | 29,222,000Source | 6,747,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -53,306,000Source | -59,965,000Source | -41,199,000Source | -41,428,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 11,052,000Source | 19,050,000Source | 6,303,000Source | 3,887,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 1,397,000Source | 1,717,000Source | 2,047,000Source | 2,944,000Source |
| Increase (Decrease) in InventoriesUSD | 98,000Source | 1,124,000Source | 4,026,000Source | 3,077,000Source |
| Increase (Decrease) in Accounts PayableUSD | 1,251,000Source | 698,000Source | 165,000Source | 1,209,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -40,170,000Source | -39,144,000Source | -39,021,000Source | -42,677,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -580,000Source | -1,361,000Source | -591,000Source | -685,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 580,000Source | 1,361,000Source | 591,000Source | 685,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 10,520,000Source | 55,870,000Source | 23,984,000Source | 7,493,000Source |
| Repayments of Long-term DebtUSD | — | — | — | 0Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -30,225,000Source | 15,364,000Source | -15,625,000Source | -35,878,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 75,708,000Source | 105,933,000Source | 90,569,000Source | 106,194,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 5,045,000Source | 3,614,000Source | 1,396,000Source | 59,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 5,000Source | -1,000Source | 3,000Source | -9,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 11,052,000Source | 19,050,000Source | 6,303,000Source | 3,887,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 241,000Source | 203,000Source | 154,000Source | 25,000Source |
| DepreciationUSD | 756,000Source | 619,000Source | 522,000Source | 412,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -86,000Source | 0Source | -4,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | -18,000Source | 55,000Source | 147,000Source | 109,000Source |
| InterestExpenseNonoperatingUSD | 5,827,000Source | 4,397,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -53,306,000Source | -59,965,000Source | -41,199,000Source | -41,428,000Source |
| Operating ExpensesUSD | 99,605,000Source | 102,448,000Source | 76,142,000Source | 59,997,000Source |
| Other Nonoperating Income (Expense)USD | 3,768,000Source | 3,977,000Source | 3,850,000Source | 1,373,000Source |
| Payments of Financing CostsUSD | 0Source | 152,000Source | 179,000Source | 778,000Source |
| Proceeds from Issuance of Common StockUSD | 8,974,000Source | 32,521,000Source | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | 793,000Source | 2,698,000Source | 728,000Source | 184,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 56,651,000Source | 51,292,000Source | 39,295,000Source | 22,469,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 88,473,000Source | 91,317,000Source | 64,509,000Source | 50,045,000Source |
| Operating Income (Loss)USD | -51,265,000Source | -59,490,000Source | -43,103,000Source | -42,527,000Source |
| Other Nonoperating Income (Expense)USD | 3,768,000Source | 3,977,000Source | 3,850,000Source | 1,373,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -53,324,000Source | -59,910,000Source | -41,052,000Source | -41,319,000Source |
| Income Tax Expense (Benefit)USD | -18,000Source | 55,000Source | 147,000Source | 109,000Source |
| Net Income (Loss) Attributable to ParentUSD | -53,306,000Source | -59,965,000Source | -41,199,000Source | -41,428,000Source |
| Earnings Per Share, BasicUSD per share | -2.04Source | -2.65Source | -1.99Source | -2.02Source |
| Earnings Per Share, DilutedUSD per share | -2.04Source | -2.65Source | -1.99Source | -2.02Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 26,084,709Source | 22,596,229Source | 20,754,375Source | 20,532,838Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 26,084,709Source | 22,596,229Source | 20,754,375Source | 20,532,838Source |
| Interest Expense (non-operating)USD | 5,827,000Source | 4,397,000Source | — | — |
| Additional Financial Items | ||||
| Gross ProfitUSD | 48,340,000Source | 42,958,000Source | 33,039,000Source | 17,470,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -53,324,000Source | — | — | — |
| Interest ExpenseUSD | — | — | 1,799,000Source | 165,000Source |
| Operating ExpensesUSD | 99,605,000Source | 102,448,000Source | 76,142,000Source | 59,997,000Source |
| Research and Development ExpenseUSD | 11,132,000Source | 11,131,000Source | 11,633,000Source | 9,952,000Source |
Filing attachments
tm2625806d1_ex99-1.htm · 8-K · 2026-09-21
Exhibit 99.1 CVRx Appoints John Landry as Chief Financial Officer Landry Brings Two Decades of Medtech and Public Company Finance Experience MINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that John Landry has been appointed Chief Financial Officer, succeeding Jared…
Read attachment ↗tm2622791d1_ex99-1.htm · 8-K · 2026-08-11
EX-99.1 2 tm2622791d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CVRx Announces Sales Leadership Transition Robert John to Depart as Chief Revenue Officer; Paul Verrastro Named Interim Head of Sales MINNEAPOLIS, August 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that Robert John, Ch…
Read attachment ↗tm2622361d1_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 tm2622361d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CVRx Reports Second Quarter 2026 Financial and Operating Results MINNEAPOLIS, August 6, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2026. Recent Highlights T…
Read attachment ↗tm2617208d1_ex99-1.htm · 8-K · 2026-06-09
EX-99.1 3 tm2617208d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CVRx Announces Chief Financial Officer Transition MINNEAPOLIS, June 9, 2026 (GLOBE NEWSWIRE) CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Jared Oasheim, the Company’s Chief Financial Officer, will be stepping down from his role to pursue other …
Read attachment ↗tm2614163d1_ex99-1.htm · 8-K · 2026-05-11
EX-99.1 2 tm2614163d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CVRx Reports First Quarter 2026 Financial and Operating Results MINNEAPOLIS, May 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2026. Recent Highlights Total…
Read attachment ↗tm2611335d1_ex99-1.htm · 8-K · 2026-04-13
EX-99.1 2 tm2611335d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CVRx Reports Preliminary First Quarter 2026 Financial Results Delivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025 Early data in 2026 shows an increase in the 30-day approval rate for Medicare Advantage prior authorizations managed by our market access team ──────────────────────────────────────────────…
Read attachment ↗